Kyntra Bio, Inc. (KYNB) stock
KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.44−0.15 (-4.18%)
Close on Nov 13, 2026Market cap $13.93MP/E 0.1Yield –
Kyntra Bio operating margin
Operating margin is operating income as a percentage of revenue.
Kyntra Bio's operating margin for the twelve months ending Jun 30, 2026 was -1089.8%. For fiscal 2025 it was -712.7%, against -507.8% the year before. The highest annual figure on record is -7.8% in fiscal 2013.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -712.7% | −204.9 |
| FY2024 | Dec 31, 2024 | -507.8% | +181.7 |
| FY2023 | Dec 31, 2023 | -689.5% | −475.6 |
| FY2022 | Dec 31, 2022 | -213.9% | −91.3 |
| FY2021 | Dec 31, 2021 | -122.6% | −13.8 |
| FY2020 | Dec 31, 2020 | -108.8% | −74.0 |
| FY2019 | Dec 31, 2019 | -34.8% | +5.9 |
| FY2018 | Dec 31, 2018 | -40.7% | +48.8 |
| FY2017 | Dec 31, 2017 | -89.5% | −62.2 |
| FY2016 | Dec 31, 2016 | -27.3% | +15.6 |
| FY2015 | Dec 31, 2015 | -42.9% | −6.5 |
| FY2014 | Dec 31, 2014 | -36.4% | −28.6 |
| FY2013 | Dec 31, 2013 | -7.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -369.7% | +175.1 |
| Q4 FY2025 | Dec 31, 2025 | -1058.1% | −830.6 |
| Q3 FY2025 | Sep 30, 2025 | -502.9% | +38271.1 |
| Q2 FY2025 | Jun 30, 2025 | -894.1% | +3756.0 |
| Q1 FY2025 | Mar 31, 2025 | -544.7% | −350.8 |
| Q4 FY2024 | Dec 31, 2024 | -227.5% | +122.9 |
| Q3 FY2024 | Sep 30, 2024 | -38774.0% | −38615.8 |
| Q2 FY2024 | Jun 30, 2024 | -4650.1% | −4451.4 |
| Q1 FY2024 | Mar 31, 2024 | -193.9% | +16.5 |
| Q4 FY2023 | Dec 31, 2023 | -350.4% | −157.9 |
| Q3 FY2023 | Sep 30, 2023 | -158.2% | +437.0 |
| Q2 FY2023 | Jun 30, 2023 | -198.7% | +63.8 |
| Q1 FY2023 | Mar 31, 2023 | -210.4% | −106.9 |
| Q4 FY2022 | Dec 31, 2022 | -192.5% | +625.0 |
| Q3 FY2022 | Sep 30, 2022 | -595.2% | −627.9 |
| Q2 FY2022 | Jun 30, 2022 | -262.4% | +286.9 |
| Q1 FY2022 | Mar 31, 2022 | -103.6% | +79.7 |
| Q4 FY2021 | Dec 31, 2021 | -817.5% | −728.3 |
| Q3 FY2021 | Sep 30, 2021 | 32.7% | −40.7 |
| Q2 FY2021 | Jun 30, 2021 | -549.3% | −350.8 |
| Q1 FY2021 | Mar 31, 2021 | -183.3% | +149.0 |
| Q4 FY2020 | Dec 31, 2020 | -89.2% | +1170.3 |
| Q3 FY2020 | Sep 30, 2020 | 73.4% | +232.7 |
| Q2 FY2020 | Jun 30, 2020 | -198.5% | −257.4 |
| Q1 FY2020 | Mar 31, 2020 | -332.3% | −127.6 |
| Q4 FY2019 | Dec 31, 2019 | -1259.5% | −1278.0 |
| Q3 FY2019 | Sep 30, 2019 | -159.3% | −12.0 |
| Q2 FY2019 | Jun 30, 2019 | 58.9% | +111.8 |
| Q1 FY2019 | Mar 31, 2019 | -204.7% | −77.5 |
| Q4 FY2018 | Dec 31, 2018 | 18.4% | +134.2 |
| Q3 FY2018 | Sep 30, 2018 | -147.4% | −91.3 |
| Q2 FY2018 | Jun 30, 2018 | -52.9% | +46.7 |
| Q1 FY2018 | Mar 31, 2018 | -127.2% | −29.3 |
| Q4 FY2017 | Dec 31, 2017 | -115.8% | −37.9 |
| Q3 FY2017 | Sep 30, 2017 | -56.1% | +17.3 |
| Q2 FY2017 | Jun 30, 2017 | -99.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -97.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -77.9% | – |
| Q3 FY2016 | Sep 30, 2016 | -73.4% | – |
See a number that looks wrong?